EWM
RCUS icon

Empirical Wealth Management’s Arcus Biosciences RCUS Stock Holding History

Empirical Wealth Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,396
Closed -$202K – 518
2022
Q1 		$202K Hold
6,396
– – 0.01% 475
2021
Q4 		$259K Buy
+6,396
New +$248K 0.01% 444

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Empirical Wealth Management's RCUS Position: Q2 2022 in Review

Empirical Wealth Management sold out of Arcus Biosciences (RCUS) in Q2 2022, closing a stake of 6,396 shares — an estimated $202K sold.

Empirical Wealth Management first reported a position in RCUS in Q4 2021 and held it in 2 quarters. The position peaked at $259K in Q4 2021. 173 funds tracked by Wall St. Rank hold RCUS as of Q2 2022.

  • Empirical Wealth Management reported no remaining Arcus Biosciences position as of Q2 2022 after selling out during the quarter.
  • Empirical Wealth Management sold 6,396 Arcus Biosciences shares in Q2 2022, an estimated $202K.
  • Empirical Wealth Management first reported a position in Arcus Biosciences in Q4 2021 and held it in 2 quarters.
  • Empirical Wealth Management's Arcus Biosciences position peaked at $259K in Q4 2021.
  • 173 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2022.

Based on Empirical Wealth Management's 13F filing for Q2 2022, filed 2 Aug 2022.